Cargando…

Real‑world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in high‑risk breast cancer subgroup patients

Numerous clinical trials have reported equal effects of tumor control between neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) in patients with breast cancer (BC). However, this conclusion has not been verified in practice. The present retrospective study evaluated if there were differe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zhensheng, Li, Yue, Liu, Yunjiang, Shang, Yuguang, Zhou, Yarong, Ji, Xiaohui, Han, Huina, Du, Kaiye, Zhang, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126659/ https://www.ncbi.nlm.nih.gov/pubmed/37113400 http://dx.doi.org/10.3892/ol.2023.13779

Ejemplares similares

Full Compliance of Adjuvant Endocrine Therapy Is Associated with Higher Disease-Free Survival in Hormone Receptor-Positive and HER2-Negative Chinese Breast Cancer Patients with First Tumor Recurrence
por: Li, Zhensheng, et al.
Publicado: (2022)

A large single-center prospective study to investigate the factors influencing the choice of breast-conserving surgery versus mastectomy in Chinese women with early breast cancer
por: Li, Zhensheng, et al.
Publicado: (2023)

Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma
por: Cheng, Daoan, et al.
Publicado: (2023)

A real‐world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non‐small cell lung cancer
por: Zhang, Baihua, et al.
Publicado: (2022)

NRBP1 negatively regulates SALL4 to reduce the invasion and migration, promote apoptosis and increase the sensitivity to chemotherapy drugs of breast cancer cells
por: Yang, Chao, et al.
Publicado: (2022)

Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer
por: Ma, Xiangmin, et al.
Publicado: (2022)

Nomogram basing pre-treatment parameters predicting early response for locally advanced rectal cancer with neoadjuvant chemotherapy alone: a subgroup efficacy analysis of FOWARC study
por: Zhang, Jianwei, et al.
Publicado: (2015)

Neoadjuvant chemotherapy for high‐risk prostatic adenocarcinoma
por: Brunner, Robert, et al.
Publicado: (2019)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
por: Zhang, Baihua, et al.
Publicado: (2023)

Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy
por: Powell, A. G. M. T., et al.
Publicado: (2020)

The effect of pelvic radiation alone on lymphocyte subgroups
por: Swanson, Gregory P., et al.
Publicado: (2020)

Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy
por: Yang, Zhao, et al.
Publicado: (2018)

Early response to upfront neoadjuvant chemotherapy (CAPOX) alone in low- and intermediate-risk rectal cancer: a single-arm phase II trial
por: Deng, Xiangbing, et al.
Publicado: (2021)

Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort
por: Jiang, Qi, et al.
Publicado: (2023)

Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma
por: Ruf, Catharina, et al.
Publicado: (2014)

Author response to: Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study
por: Kamarajah, S K, et al.
Publicado: (2021)

Combined poor diabetes control indicators are associated with higher risks of diabetic retinopathy and macular edema than poor glycemic control alone
por: Fenwick, Eva K., et al.
Publicado: (2017)

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer
por: Jayaratna, Isuru S., et al.
Publicado: (2015)

Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Colorectal Cancer: Meta-analysis of Randomized Controlled Trials
por: Huang, Lei, et al.
Publicado: (2014)

Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy
por: Li, Xinyan, et al.
Publicado: (2019)

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL
por: Olshen, Adam, et al.
Publicado: (2017)

Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials
por: Cao, Li, et al.
Publicado: (2015)

Identifying higher risk subgroups of health care workers for priority vaccination against COVID-19
por: Haq, Mohsina, et al.
Publicado: (2022)

Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities
por: Curtis, Kelly K, et al.
Publicado: (2011)

Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy
por: Chun, Jung Whan, et al.
Publicado: (2021)

Neoadjuvant chemotherapy with radical surgery vs radical surgery alone for cervical cancer: a systematic review and meta-analysis
por: Zhao, Hui, et al.
Publicado: (2019)

M1 macrophage predicted efficacy of neoadjuvant camrelizumab combined with chemotherapy vs chemotherapy alone for locally advanced ESCC: A pilot study
por: Wang, Shu, et al.
Publicado: (2023)

TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
por: Liang, Hongling, et al.
Publicado: (2021)

Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum
por: Glynne-Jones, R., et al.
Publicado: (2015)

Metabolic syndrome is a risk factor for breast cancer patients receiving neoadjuvant chemotherapy: A case-control study
por: Zhou, Zhaoyue, et al.
Publicado: (2023)

Nutritional Risk Index Predicts Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy
por: Chen, Li, et al.
Publicado: (2022)

P1041: LEUKOCYTOSIS SELECTS A SUBGROUP OF LOW-RISK PV PATIENTS IN WHOM PHLEBOTOMY-ALONE MAY BE INSUFFICIENT
por: Carobbio, Alessandra, et al.
Publicado: (2023)

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis
por: Lan, Mei, et al.
Publicado: (2017)

Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study
por: Li, Huixia, et al.
Publicado: (2023)

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA
por: Tsuboi, Masahiro, et al.
Publicado: (2021)

Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study
por: Zhao, Deping, et al.
Publicado: (2022)

Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy alone for patients with locally advanced rectal cancer: a propensity-score-matched analysis combined with SEER validation
por: Wu, Jingjing, et al.
Publicado: (2023)

Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer
por: White, Rohen, et al.
Publicado: (2016)

Identification of patients with locally advanced rectal cancer eligible for neoadjuvant chemotherapy alone: Results of a retrospective study
por: Han, Yi‐min, et al.
Publicado: (2023)

Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases
por: Ichida, Hirofumi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k3fmti0j8e5drqiubc0kj1nf3m